Ожирение и метаболизм (Feb 2022)

Growth hormone deficiency in childhood brain tumors and acute lymphoblastic leukemia survivors

  • M. G. Pavlova,
  • T. Y. Tselovalnikova,
  • A. E. Yudina,
  • O. O. Golounina,
  • A. V. Zilov,
  • N. A. Mazerkina,
  • O. G. Zheludkova,
  • V. V. Fadeev

DOI
https://doi.org/10.14341/omet12786
Journal volume & issue
Vol. 18, no. 4
pp. 484 – 495

Abstract

Read online

Thanks to modern treatment protocols, childhood cancer survivors (CCS) are a very fast-growing population nowadays. Cancer therapy inevitably leads to different late adverse effects, where endocrine disorders are highly prevalent, including growth hormone deficiency (GHD) which is the most common endocrine outcome after cancer treatment in childhood and contributes to impaired growth. Short stature is a big issue, which leads to problems in psychological and social adaptation of patients and reduces their quality of life. Impact of GH treatment on various physiological processes and global outcome of CCS is of great interest. Several studies have demonstrated an influence of GH and IGF-1 on the development/tumour growth, cell proliferation. In this regard, the issue of increasing the risk of cancer recurrence and/or the development of secondary neoplasms in CCS, causes a lot of controversy and is the subject of continuous evaluation. In this review, we went through the available data on the prevalence and pathogenesis of GHD following chemo- and radiotherapy, in particular after treatment of brain tumors and acute lymphoblastic leukaemia in childhood. In addition, here we discuss the existing problems in the diagnosis of GHD, the safety of GH replacement therapy, as well as the treatment algorithm of the GHD in adults.

Keywords